This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of -17.65% and 0.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocugen (OCGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) will provide updates on its pipeline when it reports fourth-quarter 2020 results.
4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.
Aerpio (ARPO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Aerpio (ARPO) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.
Adma Biologics (ADMA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sorrento (SRNE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Sorrento (SRNE) will provide updates on sales, earnings and pipeline when it reports fourth-quarter 2020 results.
Repligen (RGEN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.
ADMA Biologics (ADMA) in Focus: Stock Moves 6.6% Higher
by Zacks Equity Research
ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Adma Biologics (ADMA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 9.52% and 7.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for ADMA Biologics' (ADMA) Q3 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.
Analysts Estimate Adma Biologics (ADMA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Is the Options Market Predicting a Spike in ADMA Biologics (ADMA) Stock?
by Zacks Equity Research
Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.
ADMA Biologics (ADMA) Surges: Stock Moves 8.6% Higher
by Zacks Equity Research
ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Are Options Traders Betting on a Big Move in ADMA Stock?
by Zacks Equity Research
Investors need to pay close attention to ADMA stock based on the movements in the options market lately.
Adma Biologics (ADMA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of -21.05% and -24.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in ADMA Stock?
by Zacks Equity Research
Investors need to pay close attention to ADMA stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in ADMA Biologics (ADMA) Stock?
by Zacks Equity Research
Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.
Adma Biologics (ADMA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of -100.00% and -4.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?